NEW HAVEN — Rib-X Pharmaceutical has named Mary Szela to chair its board of directors. Szela has a 25-year career as a pharmaceutical executive. She spent more than two decades in senior roles at Abbott Laboratories, most recently as senior vice president for global strategic marketing and services of the Pharmaceutical Products Group. Before that she was senior vice president of U.S. Pharmaceuticals, an $8 billion business. For more than seven years Szela directed the development, launch and growth of eight new pharmaceutical products, including leadership of Abbott’s flagship product, Humira.
Headquartered in New Haven, Rib-X Pharmaceuticals is a biopharmaceutical company developing new antibiotics to provide coverage, safety and convenience for the treatment of serious and life-threatening infections.